logo
Share SHARE
FONT-SIZE Plus   Neg

4SC's Anti-Cancer Drug Resminostat Achieves Median Overall Survival Of 8 Months

4SC AG (FSCGF.PK) announced the publication of convincing overall survival data from a Phase II study with its lead anti-cancer drug resminostat applied as a novel combination therapy approach with sorafenib in second-line advanced liver cancer at the 2012 annual meeting of the International Liver Cancer Association in Berlin, Germany, on September 16, 2012. The international, open-label, two-arm SHELTER trial enrolled patients with advanced liver cancer who had demonstrated proven radiological tumor progression under first-line therapy with the cancer drug sorafenib.

The study investigated safety and efficacy of resminostat as a monotherapy and in combination with sorafenib in this patient group with currently no approved treatment option.

Final median overall survival of 8.0 months was determined in the resminostat/sorafenib combination 'intend-to-treat' population, i.e. all study patients who were treated with the combination of 600 mg resminostat total daily dose and 400 mg sorafenib TDD. According to the company, the data for the resminostat/sorafenib combination therapy showed a progression-free survival rate after 12 weeks of treatment of 70.0% and a median PFS of 4.7 months.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Automotive parts retailer AutoZone, Inc. on Tuesday reported a 6 percent increase in profit for the third quarter from last year, reflecting growth in sales and higher inventory on new store openings. However, both revenue and earnings per share for the quarter missed analysts' expectations. Toll Brothers, Inc. (TOL), the nation's leading builder of luxury homes, reported second-quarter net income of $89.1 million, or $0.51 per share, compared to $67.9 million, or $0.37 per share, prior year. Pre-tax income increased to $140.4 million from $86.5 million. On average, 18 analysts polled by... German conglomerate Bayer AG said it has made an all-cash offer to acquire U.S. competitor Monsanto for $122 per share or an aggregate value of $62 billion. Bayer expects the deal to reinforce it as a Life Science company with a deepened position. Responding to recent media reports, agricultural products giant Monsanto recently had disclosed that it had received an unsolicited proposal from Bayer.
comments powered by Disqus
Follow RTT